Medicine
Personalized Medicine Based on Pharmacogenomic Testing
Quick fact
A single genetic variant in the CYP2D6 gene can turn a standard dose of codeine into a fatal overdose because the drug is converted to morphine faster than normal.
Why this is interesting
You and your friend take the same antibiotic — it cures them but lands you in the hospital. Why? The answer might be written in your DNA.
Read the full explanation
Understanding Personalized Medicine Based on Pharmacogenomic Testing
Imagine drugs as keys and your body's enzymes as locksmiths. Everyone has locksmiths, but the instructions for building them come from your genes. Pharmacogenomic testing reads those instructions for a set of genes known to affect drug processing. When you take a drug, your liver enzymes break it down, activate it, or help your body eliminate it. Some people have a genetic variant that makes an enzyme work too quickly, too slowly, or not at all. This means the same dose of the same drug can build up to toxic levels in one person, not work at all in another, and be just right in a third. A simple cheek swab or blood sample can reveal these variants before a prescription is written, allowing the doctor to choose a different drug or adjust the dose based on your predicted response.
A deeper explanation
Pharmacogenomic testing works by analyzing specific genes that encode drug-metabolizing enzymes, drug transporters, or drug targets. Among the most important are cytochrome P450 genes such as CYP2D6, CYP2C19, and CYP2C9. Tiny changes in these genes—single nucleotide variants, insertions, deletions, or extra copies—create different versions of enzymes. Depending on the variants a person carries, they are classified as poor, intermediate, extensive, or ultrarapid metabolizers. This classification predicts how fast a drug is cleared from the body. For example, clopidogrel, a blood thinner, must be activated by CYP2C19; poor metabolizers get little benefit. Warfarin dosing depends on VKORC1 and CYP2C9 to avoid bleeding, and abacavir hypersensitivity is predicted by the HLA-B57:01 variant. Rather than treating everyone with a standard dose, pharmacogenomics lets clinicians tailor therapy to each patient's genetic profile—demonstrating the core principle of personalized medicine: using a patient's own biology to guide treatment, prevent adverse reactions, and maximize effectiveness.